<DOC>
	<DOCNO>NCT02346942</DOCNO>
	<brief_summary>The Primary objective study understand rheumatoid arthritis ( RA ) population national integrate delivery network treat first- second-line biologic disease modify anti-rheumatic drug ( bDMARD ) therapy ( without Methotrexate ) evaluate switch pattern reason switch another bDMARD .</brief_summary>
	<brief_title>Factors Associated With Biologic DMARD Switching</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Diagnosis RA ( ICD9 714.xx ) anytime study time period 1/1/2007 10/31/2012 Patients â‰¥18 year age diagnosis date Required 6 month preindex 12 month postindex continuous membership drug benefit eligibility database Patients le 18 year age diagnosis date If diagnosis Crohn 's disease , psoriasis , psoriatic arthritis , ulcerative colitis , ankylose spondylitis , regional enteritis , anal fistula preindex period Patients &lt; 7 day supply adalimumab etanercept Patients currently clinical trial study If patient secondline cohort 1 prior bDMARD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>